Undisclosed HER2Bi-armed ATC

P2, N=8, Terminated, Barbara Ann Karmanos Cancer Institute | Unknown status --> Terminated; Primary co-investigator leaving the institution & funding transfer.

P2, N=43, Terminated, Barbara Ann Karmanos Cancer Institute | N=63 --> 43 | Unknown status --> Terminated

P2, N=15, Active, not recruiting, Barbara Ann Karmanos Cancer Institute | Recruiting --> Active, not recruiting | N=33 --> 15 | Trial completion date: Dec 2021 --> Jun 2023

HER2Bi- or EGFRBi-armed CART19 exhibited specific cytotoxicity against multiple HER2/EGFR/CD19 tumor targets in overnight and long-term serial killing assays. CART19 showed improved survival and were resistant to exhaustion after prolonged repeated exposure to tumor cells.

mCRPC patients with 0-1 performance status (PS) and normal liver, kidney and marrow function, pre or post docetaxel chemotherapy were eligible. The combination regimen of pembrolizumab and BATs appears to be worthy of future exploration in a larger trial in mCRPC. Clinical trial information: NCT03406858. Research Funding: Merck Inc and NIH Cancer Center Support Grant CA-22453, Pharmaceutical/Biotech Company, U.S. National Institutes of Health.

mCRPC patients with 0-1 performance status (PS) and normal liver, kidney and marrow function, pre or post docetaxel chemotherapy were eligible. The combination regimen of pembrolizumab and BATs appears to be worthy of future exploration in a larger trial in mCRPC. Clinical trial information: NCT03406858. Research Funding: Merck Inc and NIH Cancer Center Support Grant CA-22453, Pharmaceutical/Biotech Company, U.S. National Institutes of Health.